In addition, HIF1α is an attractive target for improving the systemic iron status of patients with ID, since HIF1α pathway activation targets genes involved in the promotion of blood oxygenation and iron homeostasis, particularly TF and TFRC. Accordingly, an interplay between iron levels and the HIF1α pathway may be a crucial mechanism underlying ID in IBD patients. The gene discussed is TFRC; the disease is inflammatory bowel disease.